Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart Plus Anlotinib and Chemotherapy in Unresectable Stage III NSCLC
NCT07643350Phase 2Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Third Xiangya Hospital, Central South University. Planned start May 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07643350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643350.